NCT00683514View on ClinicalTrials.gov

Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

201

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

September 30, 2011

Conditions
NSCLC
Interventions
DRUG

Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)

"q 28 days :~* 50 mg/m2 oral vinorelbine d1, d8, d15~* 20 mg/m2/d cisplatin from d1 to d4"

DRUG

Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)

"q 21 days :~* 60 mg/m2 oral vinorelbine d1,d8 for cycle 1 or 80 mg/m2 oral vinorelbine d1,d8 for cycle 2~* 80 mg/m2 cisplatin d1"

Trial Locations (1)

D-79111

Pierre Fabre Pharma GmbH, Freiburg im Breisgau

All Listed Sponsors
collaborator

Pierre Fabre Pharma GmbH

INDUSTRY

lead

Pierre Fabre Medicament

INDUSTRY

NCT00683514 - Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter